RIO DE JANEIRO, BRAZIL - After being granted ANVISA's (Brazilian Health Regulatory Agency) authorization to manufacture the Active Pharmaceutical Ingredient (API) for AstraZeneca's vaccine, Fiocruz projects the delivery of the first doses produced with the national input to the Ministry of Health in February 2022, when the quality control tests that occur after the final processing of the vaccine are concluded.
The vaccine will now be produced entirely in Brazil, helping to reduce dependence on other countries, such as India. Fiocruz began producing the national API in June 2021, after a technology transfer from AstraZeneca, foreseen in the immunizer . . .
To read the full NEWS and much more, Subscribe to our Premium Membership Plan. Already Subscribed? Login Here